Jakavi Tablet contains Ruxolitinib. It is an inhibitor of Janus kinase (JAK) that is mainly used to treat cancer and several blood problems.

Brand Name: Jakavi

Composition: Ruxolitinib

Mechanism of Action:

JAK1 and JAK2 enzymes, which are involved in the signaling pathways for blood cell formation and inflammatory reactions, are inhibited by rufolitinib. By doing this, it lessens symptoms like spleen enlargement and systemic inflammation and helps regulate aberrant blood cell synthesis.

Uses:

• Myelofibrosis
• Polycythemia Vera
• Graft-versus-Host Disease

Dosage and Administration:

It is advised to take Jakavi with or without food. The tablet should not be split, chewed, or crushed. Skip the missed dose and take the subsequent one at the scheduled time. Avoid taking two doses at once.

Side Effects:

• Anemia
• Thrombocytopenia
• Headache
• Nausea
• Vomiting
• Dizziness
• Increased risk of infections

Safety Advise:

Lungs  

The safety of Jakavi for individuals with lung issues is uncertain. Kindly speak with your healthcare provider.

Liver  

The safety of Jakavi for individuals with liver issues is uncertain. Kindly speak with your healthcare provider.

Kidney  

The safety of Jakavi for individuals with Kidney issues is uncertain. Kindly speak with your healthcare provider.

  Pregnancy  

Jakavi should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Jakavi while nursing is most likely dangerous. Kindly speak with your healthcare provider. 

Storage:

Maintain storage between 15°C and 30°C (59°F and 86°F). Keep away from moisture and in a dry location. Store away from moist areas like bathrooms.

How to use this Medication?

Ruxolitinib is available as an oral tablet. It is often taken twice a day, either with or without food. Take ruxolitinib daily at around the same times. Pay close attention to the instructions on your prescription label, and ask your pharmacist or doctor to clarify any parts you don't understand. Ruxolitinib should be taken precisely as prescribed. Never take more or less of it, or take it more frequently than your doctor has suggested.

Ruxolitinib is begun at a low dose for PV or myelofibrosis and increased progressively every two weeks. Dosing for GVHD is modified according to response, and for chronic patients, weaning is done gradually after six months.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Novartis India Ltd

Address: Sandoz House, Shiv Sagar Estate, Worli Mumbai -400 018, India

Country of origin: Switzerland